Keller-Lab@Charite

We aim at identifying mechanisms of cancer pathogenesis to develop novel mechanism-based and molecular-informed cancer therapies

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

💡Möglicher neuer Ansatz gegen #Bauchspeicheldrüsenkrebs: Wie eine #CharitéBerlin-Studie jetzt zeigt, führt die gleichzeitige Blockade zweier voneinander abhängiger „Zahnrädchen“ in der Krebszelle zur Hemmung des Tumorwachstums – zumindest im Tiermodell.👉https://t.co/qCsiZyfVqs

[Keller-Lab@Charite @lab_keller]

Early View | Haematologica https://t.co/oiLGn0wlSK

Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma!
Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.

[Keller-Lab@Charite @lab_keller]

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine https://t.co/K9n4nq8Rzn

[Science Signaling @scisignal]

Engineering a mouse model of #autoimmunity, researchers at @ChariteBerlin have made strides in understanding the basis of a mysterious and rare autoimmune disorder named STAT3GOF syndrome and identified sex-specific differences in the disorder. @lab_keller https://t.co/zLNu0oj61N

[Science Signaling @scisignal]

Researchers generated a new mouse model of #STAT3GOF syndrome that can recapitulate the IL-6-gp130-STAT3 pathway and multi-organ autoimmunity—addressing the lack of reliable animal models for this rare autoimmune condition. @lab_keller @ChariteBerlin https://t.co/I0uSOWcyZo

[Eilers Lab @MYCGyvers]

CIAO @_WolfLab 🤍
Today we say goodbye to Anneli and Elmar after more than a decade in the institute. Both of you shaped our institute and the science done @Uni_WUE! We wish you all the best for your new adventure @kieluni!

[Keller-Lab@Charite @lab_keller]

Check out our recent publication in EMBO Mol Med:
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response
https://t.co/1d29pVdKwl

[Keller-Lab@Charite @lab_keller]

Great opprtunity for a postdoctoral researcher/team leader at Keller-Lab@Charite

https://t.co/lqoBCS7Kh2

Looking forward to your application!

[Keller-Lab@Charite @lab_keller]

We are looking for a talented PhD student. See our announcement at Charité Homepage and Jobvector!

[Annals of Oncology @Annals_Oncology]

In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer
https://t.co/iKmORudpXJ

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

Dr. Uta Demel von #CharitéBerlin und @MDC_Berlin ist für eine ihrer Publikationen mit dem Forschungspreis der Arbeitsgemeinschaft DAG-HSZT ausgezeichnet worden. Herzlichen Glückwunsch! https://t.co/E3jIWbWImW

[GRK2243 @grk2243]

It's not all about #ubiquitin: Listen to Uta Demel from @lab_keller @MDC_Berlin how inhibition of SUMOylation leads to increased antigen presentation and T-cell activation

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

A team of researchers from #CharitéBerlin reveal in @jclinicalinvest how cancer cells can evade immunosurveillance. A cellular signaling pathway activated as part of this process may offer a new target for more effective cancer immunotherapy treatments. https://t.co/M3BcpmKn8r

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

New treatment strategy for #PancreaticCancer: Writing in @PNASNews, a team of researchers from #CharitéBerlin describe how a key factor which enables the suppression of cancer cell death (#apoptosis) can be used to block #TumorGrowth. https://t.co/1luowldyzW

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

Writing in @NatureComms, a team of researchers from #CharitéBerlin and @goetheuni untangle a key process involved in #Lymphoma development, which controls DNA damage repair and offers a potential treatment target. https://t.co/oKpsOoy52A

[Keller-Lab@Charite @lab_keller]

Richie, Stefan and coworkers reveal a critical role for CXCR4 in aggressive forms of CLL :
https://t.co/pTJcjTsThx

[Özcan Çınar @cinar_ozcan]

After years of hard work (literally) involving blood, sweat and tears, I am thrilled to be able share this! We developed TCRs targeting one of the most common mutations in #lymphoma. Online at @jitcancer : https://t.co/vi0P8PFgzC
@MDC_Berlin @ChariteBerlin

[Keller-Lab@Charite @lab_keller]

Important preclinical study to advance tumor-specific adoptive T cell therapy for patients with MYD88 mutant lymphoma. Congratulations to Antonia Busses group https://t.co/oL9wud2JeY

[Ricardo Lange @RicardoLange4]

Sorry, für heute muss ich erst einmal weg. Ich bin echt enttäuscht und fassungslos zugleich. Mit Beleidigungen kann ich umgehen, aber einige Wortmeldungen sind für mich echt harter Tobak.

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

After 20 years of preliminary research in the labs of @MDC_Berlin & #CharitéBerlin, a new T-cell immunotherapy against #MultipleMyeloma is now in clinical trials. The innovative treatment is designed to teach the immune system to fight the cancer cells. https://t.co/NsNUl9hAiR